Treatment of psychosis in Parkinson´s disease
References
Additional references
Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewer´s Handbook 4.2.1 [updated December 2003]. In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd., 2004.
Altman DG, Matthews JN. Statistics notes. Interaction 1: Heterogeneity of effects. BMJ 1996;313(7055):486.
Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000;25;55(2):281‐8.
Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment‐induced hallucinations. Annals of neurology 1993;34(5):710‐4.
Cummings JL. Depression and Parkinson's disease: a review. The American journal of psychiatry 1992;149(4):443‐54.
Dixon RA, Munro JF, Silcocks RP. Checklists for critical Appraisal. The Evidence Based Medicine Workbook: Critical Appraisal for Clinical Problem Solving. Butterworth‐Heinemann Medical, Appendix 1, 1997.
Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug‐induced psychiatric states. Advances in neurology 1995;65:115‐38.
Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123 (Pt 4):733‐45.
Fischer P, Danielczyk W, Simanyi M, Streifler MB. Dopaminergic psychosis in advanced Parkinson's disease. Advances in neurology 1990;53:391‐7.
Friedman JH. The management of the levodopa psychoses. Clinical neuropharmacology 1991;14(4):283‐95.
Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43(11):2227‐9.
Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45(4):669‐71.
Ives NJ, Stowe RL, Clarke CE, Gray R, Wheatley K, Shah L. Dopamine agonist therapy in early Parkinson´s disease: A systematic review of randomised controlled trials. Movement disorders 2004;19, Suppl. 9:209.
Klawans HL. Psychiatric side effects during the treatment of Parkinson's disease. Journal of neural transmission. Supplementum 1988;27:117‐22.
Lieberman A, Kupersmith M, Estey E, Goldstein M. Treatment of parkinson's disease with bromocriptine. The New England journal of medicine 1976;295(25):1400‐4.
Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double‐blind study. New York state journal of medicine 1987;87(12):646‐9.
Movement Disorder Society. Management of Parkinson's disease: an evidence‐based review. Movement disorders 2002;17 Suppl 4:1‐166.
Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Movement disorders 1994;9(1):40‐7.
Parkinson´s Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. BMJ 1993;307(6902):469‐72.
Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. Journal of neurology 2001;248 Suppl 3::12‐21.
Poewe W. Psychosis in Parkinson's disease. Movement disorders 2003;18 Suppl 6:S80‐7.
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa‐treated Parkinson's disease patients. Parkinson Study Group. Annals of neurology 1997;42(5):747‐55.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284(15):1931‐8.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five‐year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. The New England journal of medicine 2000;342(20):1484‐91.
Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double‐blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997;48(2):363‐8.
Timberlake WH, Vance MA. Four‐year treatment of patients with parkinsonism using amantadine alone or with levodopa. Annals of neurology 1978;3(2):119‐28.
Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. The Canadian journal of neurological sciences 1992;19(1 Suppl):142‐6.
